Literature DB >> 8594690

Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria.

F O ter Kuile1, C Luxemburger, F Nosten, K L Thwai, T Chongsuphajaisiddhi, N J White.   

Abstract

The factors which identify patients at risk of treatment failure were characterized in 1590 children and adults with uncomplicated falciparum malaria treated with 15 or 25 mg/kg of mefloquine on the borders of Thailand. Six independent predictors of failure were identified using multiple logistic regression. Age < or = 2 years (odds ratio [OR] 4.54), 3-15 years (OR 4.4), vomiting < 30 min after a single dose of 25 mg/kg (despite re-administration of the dose) (OR 2.5) and diarrhoea after treatment (OR 3.6) were the strongest predictors of failure by day 7. Parasitaemias > 10 000/mm3 (OR 1.4), and fever with a history of recent vomiting (OR 1.6) were risk factors for recrudescence of the infection between days 10 and 28. Patients treated with mefloquine in the previous 2 months were also at increased risk of failure (OR 2.38), particularly if they were anaemic (haematocrit < 30%) (OR 5.96), which suggested that they had recrudescent infections at presentation. Combined, these 6 factors identified half of all treatment failures. Vomiting and diarrhoea accounted for 24% of the early failures in children. Patients at increased risk of treatment failure should be monitored closely and given early alternative treatment if fever and parasites persist for > or = 3 d.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594690     DOI: 10.1016/0035-9203(95)90435-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  32 in total

1.  Antimalarial drugs clear resistant parasites from partially immune hosts.

Authors:  P Cravo; R Culleton; P Hunt; D Walliker; M J Mackinnon
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  Malaria parasites giving rise to recrudescence in vitro.

Authors:  Shusuke Nakazawa; Takashi Maoka; Haruki Uemura; Yoshihiro Ito; Hiroji Kanbara
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 3.  Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria.

Authors:  A A A Omari; C Gamble; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.

Authors:  N J White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  The de novo selection of drug-resistant malaria parasites.

Authors:  N J White; W Pongtavornpinyo
Journal:  Proc Biol Sci       Date:  2003-03-07       Impact factor: 5.349

Review 6.  Antimalarial drug resistance.

Authors:  Nicholas J White
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 7.  New antimalarials. A risk-benefit analysis.

Authors:  F Nosten; R N Price
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

8.  In vivo parasitological measures of artemisinin susceptibility.

Authors:  Kasia Stepniewska; Elizabeth Ashley; Sue J Lee; Nicholas Anstey; Karen I Barnes; Tran Quang Binh; Umberto D'Alessandro; Nicholas P J Day; Peter J de Vries; Grant Dorsey; Jean-Paul Guthmann; Mayfong Mayxay; Paul N Newton; Piero Olliaro; Lyda Osorio; Ric N Price; Mark Rowland; Frank Smithuis; Walter R J Taylor; François Nosten; Nicholas J White
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

9.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

10.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.

Authors:  Nicholas J White; Wirichada Pongtavornpinyo; Richard J Maude; Sompob Saralamba; Ricardo Aguas; Kasia Stepniewska; Sue J Lee; Arjen M Dondorp; Lisa J White; Nicholas P J Day
Journal:  Malar J       Date:  2009-11-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.